Review: Gene-Modified Dendritic Cells for Use in Tumor Vaccines
dc.contributor.author | Kirk, Christopher J. | en_US |
dc.contributor.author | Mulé, James J. | en_US |
dc.date.accessioned | 2009-07-10T19:00:37Z | |
dc.date.available | 2009-07-10T19:00:37Z | |
dc.date.issued | 2000-04-10 | en_US |
dc.identifier.citation | Kirk, Christopher J.; Mulé, James J. (2000). "Review: Gene-Modified Dendritic Cells for Use in Tumor Vaccines." Human Gene Therapy 11(6): 797-806 <http://hdl.handle.net/2027.42/63168> | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/63168 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=10779157&dopt=citation | en_US |
dc.description.abstract | Dendritic cells (DCs) are potent antigen-presenting cells capable of priming activation of naive T cells. Because of their immunostimulatory capacity, immunization with DCs presenting tumor antigens has been proposed as a treatment regimen for cancer. The results from translational research studies and early clinical trials point to the need for improvement of DC-based tumor vaccines before they become a more broadly applicable treatment modality. In this regard, studies suggest that genetic modification of DCs to express tumor antigens and/or immunomodulatory proteins may improve their capacity to promote an antitumor response. Because the DC phenotype is relatively unstable, nonperturbing methods of gene transfer must be employed that do not compromise viability or immunostimulatory capacity. DCs expressing transgenes encoding tumor antigens have been shown to be more potent primers of antitumor immunity both in vitro and in animal models of disease; in some measures of immune priming, gene-modified DCs exceeded their soluble antigen-pulsed counterparts. Cytokine gene modification of DCs has improved their capacity to prime tumor antigenspecific T cell responses and promote antitumor immunity in vivo. Here, we review the current status of genemodified DCs in both human and murine studies. Although successful results have been obtained to date in experimental systems, we discuss potential problems that have already arisen and may yet be encountered before gene-modified DCs are more widely applicable for use in human clinical trials. | en_US |
dc.format.extent | 307665 bytes | |
dc.format.extent | 2489 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Mary Ann Liebert, Inc., publishers | en_US |
dc.title | Review: Gene-Modified Dendritic Cells for Use in Tumor Vaccines | en_US |
dc.type | Article | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.identifier.pmid | 10779157 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/63168/1/10430340050015419.pdf | |
dc.identifier.doi | doi:10.1089/10430340050015419 | en_US |
dc.identifier.source | Human Gene Therapy | en_US |
dc.identifier.source | Human Gene Therapy | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.